Drugs / T3P-Y058-739
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05120596 | Apr 2022 → Feb 2027 expected | neoplasm | T3 Pharmaceuticals AG | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T3P-Y058-739 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05120596 ↗ |
| Known as | T3P | “First in Human Study of T3P-Y058-739 (T3P)” NCT05120596 ↗ |
| Modality | Other / unclassified | “a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica” NCT05120596 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT05120596 ↗ |